Download the presentation here: PDF

More documents

Recommendations

Info

Incredible POC Data for OA of the Knee • At week 12, 70+% of patients reported a 30% reduction in pain at all doses, with more than 50% having a 50% reduction in pain and 10-30% having a 90% reduction in pain. • Compared to an NSAID with 30-50% of patients reporting a 30% reduction in pain, dropping to 20- 40% having a 50% reduction and less than 20% having a 90% reduction in pain. Pfizer Analyst and Investor Meeting Oct. 28, 2008 88 © Defined Health, 2009 Pain Insight Briefing
Concerning, but Transient Adverse Events • Headache, upper respiratory tract infection, paresthesias, hypoesthesias, and arthralgia or joint pain, were the most frequently reported adverse events for patients treated with tanezumab. • In terms of withdrawals due to adverse events, only arthralgia or worsening diabetes led to the withdrawal in more than one patient across the treatment arms. • Seven patients experienced a serious adverse event in this study. – Chest pain (placebo) – Cellulitis, appendicitis (10µg/kg) – Breast cancer, bacterial arthritis (50µg/kg) – Syncope, lumbar spine stenosis (200µg/kg) Pfizer Analyst and Investor Meeting Oct. 28, 2008 89 © Defined Health, 2009 Pain Insight Briefing
Page 1 and 2:
Game Changing Plays in the Pain Mar
Page 3 and 4:
Our Disclaimer 3 The information in
Page 5 and 6:
Everyone Hurts “Pain is whatever
Page 7 and 8:
It’s A Big Market with a Few Domi
Page 9 and 10:
$ Millions But Few “Big Pharma-Si
Page 11 and 12:
Pain Historically: Drug Delivery ha
Page 13 and 14:
It’s Getting Tougher Labopharm La
Page 15 and 16:
The Risk : Reward Profile for Novel
Page 17 and 18:
Current Standard of Care for Pain
Page 19 and 20:
Leaving Plenty of Unmet Need to Be
Page 21 and 22:
In the Meantime, Let’s Teach Old
Page 23 and 24:
A Better NSAID: NicOx • Naproxcin
Page 25 and 26:
A Better NSAID: NicOx 25 Company pr
Page 27 and 28:
A Better NSAID: Pozen / AstraZeneca
Page 29 and 30:
The First-to-Market Topical NSAIDs
Page 31 and 32:
Even So, Flector is Expected To Be
Page 33 and 34:
Now We Have a Patch and a Gel Volta
Page 35 and 36:
The Need is Clear 35 © Defined Hea
Page 37 and 38: Progenics / Wyeth: Making Opioids M
Page 39 and 40: Adolor / Pfizer: Making Opioids Mor
Page 41 and 42: Like All Things CNS, It’s Not So
Page 43 and 44: A New, and Better Opioid from J&J /
Page 45 and 46: A New, and Better Opioid from J&J /
Page 47 and 48: Opioid Abuse Deterrence 47 © Defin
Page 49 and 50: King Pharmaceuticals: Making Big Be
Page 51 and 52: But Also Significant Hurdles • Te
Page 53 and 54: The Technologies are Not the Proble
Page 55 and 56: The Real Issue is Risk Management
Page 57 and 58: Fentanyl: Again, REMS is the Big Re
Page 59 and 60: Lessons from Fentora 59 What the FD
Page 61 and 62: For Some Mechanisms, the US Regulat
Page 63 and 64: FAAH Pipeline 63 Compound SSR 10101
Page 65 and 66: FAAH Pipeline KDS-4103, acquired by
Page 67 and 68: Addressing the Big Problem 67 >50%
Page 69 and 70: New MOA Challenges 69 NeuroDiscover
Page 71 and 72: New MOA Challenges 71 The identific
Page 73 and 74: TRPV1 • The transient receptor po
Page 75 and 76: TRPV1: Target for Novel Analgesics
Page 77 and 78: TRPV1 Antagonists: Hot … Too Hot
Page 79 and 80: TRPV1 Antagonist Pipeline Compound
Page 81 and 82: TRPV1 Antagonist Pipeline 81 Compou
Page 83 and 84: TRPV3: Hopeful, But Too Early to Te
Page 85 and 86: Good Phase III Data, An Accepted ND
Page 87: Pfizer Pursuing Multiple Chronic Pa
Page 91 and 92: Will NGF for Pain Be Like TNF is fo
Page 93 and 94: Repurposed anti-TNF Antibodies for
Page 95 and 96: What’s Next for Pain? • Continu
show all

Download the presentation here: PDF

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?